Clinical Trial Update: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating treating metastatic castration-resistant prostate cancer with PROVENGE (sipuleucel-T) plus one infusion of sipuleucel-T; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• PROVENGE (sipuleucel-T)
• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: Dendreon | Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Status: RECRUITING